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Context: Patients with adrenal and extra-adrenal abdominal paraganglioma (PGL) almost invari-
ably have increased plasma and urine concentrations of metanephrines, the O-methylated me-
tabolites of catecholamines. We report four cases of biochemically silent abdominal PGL, in which
metanephrines were normal despite extensive disease.
Objective: Our objective was to identify the mechanism underlying the lack of catecholamine
hypersecretion and metabolism to metanephrines in biochemically silent PGL.
Design: This is a descriptive study.
Setting: The study was performed at a referral center.
Patients: One index case and three additional patients with large abdominal PGL and metastases
but with the lack of evidence of catecholamine production, six patients with metastatic cate-
cholamine-producing PGL and amutation of the succinate dehydrogenase subunit B (SDHB) gene,
and 136 random patients with catecholamine-producing PGL were included in the study.
Main Outcome Measures: Plasma, urine, and tumor tissue concentrations of catecholamines and me-
tabolites were calculatedwith electronmicroscopy and tyrosine hydroxylase immunohistochemistry.
Results: All four patients with biochemically silent PGL had an underlying SDHBmutation. In the
index case, the tumor tissue concentrationof catecholamines (1.8 nmol/g)was less than 0.01%that
of themedian (20,410nmol/g) for the136patientswith catecholamine-producing tumors. Electron
microscopy showed the presence of normal secretory granules in all four biochemically silent PGLs.
Tyrosine hydroxylase immunoreactivity was negligible in the four biochemically silent PGLs but
abundant in catecholamine-producing PGLs.
Conclusions: Patients with SDHBmutationsmay presentwith biochemically silent abdominal PGLs
due to defective catecholamine synthesis resulting from the absence of tyrosine hydroxylase.
Screening for tumors in patients with SDHB mutations should not be limited to biochemical tests
of catecholamine excess. (J Clin Endocrinol Metab 93: 4826–4832, 2008)
Paragangliomas (PGLs) derive from either sympathetic tissuein adrenal and extra-adrenal locations, or from parasym-
pathetic tissueof theheadandneck (1).Adrenal PGLsareusually
referred to as pheochromocytomas. Most patients with adrenal
and extra-adrenal abdominal PGLs have increased plasma and
urine concentrations of catecholamines (dopamine, norepineph-
rine, and epinephrine). In about 8–9%of patients with sporadic
PGL and 21–31% with hereditary PGL, plasma concentrations
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and urinary outputs of catecholamines are normal (2). Never-
theless, such patients invariably have elevated plasma concen-
trations of themetanephrines, normetanephrine, andmetaneph-
rine. These O-methylated metabolites of norepinephrine and
epinephrine are produced continuously within tumor cells and
independently of catecholamine release,which canbe variable or
negligible, even in patients with large tumors (3). Exceptions in
which plasma metanephrines can be normal include patients
with very small tumors (1 cm) that do not synthesize and me-
tabolize sufficient amounts of catecholamines to produce posi-
tive test results (4). Other rare exceptions include patients with
PGLs that only produce dopamine andwhichmaybe detected by
increases in plasmamethoxytyramine, theO-methylatedmetab-
olite of dopamine (5, 6). In contrast to PGLs derived from sym-
pathetic tissue, the vast majority of head and neck PGLs do not
produce significant amounts of catecholamines (7).
Although there have been several reports of patients with
abdominal PGLs of considerable size, yet normal plasma and
urine catecholamine concentrations (8–13), it is unclearwhether
the normal catecholamines in these patients reflect defective se-
cretion or an absence of releasable stores due to defects in syn-
thesis or storage. Here, we report data from four patients with
abdominal PGLs due to mutations of the gene for succinate de-
hydrogenase B (SDHB), all with large tumors or extensive met-
astatic disease and all without evidence of catecholamine hyper-
secretion. More importantly, all patients had normal plasma
concentrations and urinary outputs of metanephrines, tumor bi-
omarkers commonly recognized toprovidepositive test results in
all but the smallest of tumors. To identify the defect underlying
the lack of catecholamine hypersecretion and metabolism to
metanephrines, we examined the biochemical, ultrastructural,
and functional properties of the tumors in these patients. Data
were compared with those from another group of patients with
PGLs due to SDHB mutations, all of which showed consistent
evidence of catecholamine production and metabolism.
Patients and Methods
Patients
Our index case no. S1, was a patient with a mutation of the SDHB
gene and a large abdominal PGL with additional metastatic disease but
the lack of evidence of catecholamine hypersecretion. We subsequently
studied three additional patients (nos. S2–4) with malignant PGL and
lack of catecholamine hypersecretion. All patients were included in a
previous report on SDHB-related PGL (11), in which the lack of cate-
cholamine hypersecretion was documented but in which the mechanism
was not investigated or identified. Six patients (nos. C1–6) with meta-
static catecholamine-producing SDHB-associated PGLs were included
in the study for comparison. Individual patient characteristics are given
in Table 1.
In aprevious study,we showeda strongpositive relationshipbetween
tumor size and summed plasma concentrations of metanephrine and
normetanephrine (4). The correlations between tumor volume, catechol-
amine content, and summed plasma concentrations of normetanephrine
and metanephrine in the 136 patients with catecholamine-producing
PGLs from the previous report (4) were used as a comparison for our
index case (no. S1). Samples of frozen tissue from primary tumors were
not available from the three other patients (nos. S2–4) for this part of the
study because these patients underwent surgery outside the National
Institutes ofHealth (NIH), before referral to our center. The protocol for
this study was approved by the Institutional Review Board of the Na-
tional Institutes of Child Health and Human Development at the NIH.
All patients provided written informed consent.
Plasma, urine, and tissue catecholamines and
metabolites
Blood sampleswere collected into heparin-containing tubes by use of
a forearm venous cannula, with patients supine for at least 20min before
sampling. Samples were collected on ice, and plasma was separated and
stored at80 C before analysis according to recommended procedures
(14). Plasma was assayed by HPLC for concentrations of dopamine,
norepinephrine, epinephrine, and their free O-methylated metabolites
methoxytyramine, normetanephrine, and metanephrine as described
previously (15, 16). The 24-h urinary outputs of catecholamines and
deconjugated (free plus conjugated) fractionated metanephrines were
measured by liquid chromatography with electrochemical detection or
tandem mass spectroscopy under a contract between the NIH Clinical
Center and an outside commercial laboratory (Mayo Medical Labora-
tories, Rochester, MN).
Concentrations of dopamine, norepinephrine, and epinephrine in
samples of frozen tumor tissue were quantified by liquid chromatogra-
phywith electrochemical detection (4). Sampleswere obtainedwithin 90
min of surgical removal of PGL, weighed, frozen, and homogenized in
five to 10 volumes of 0.4 M perchloric acid containing 0.5 mM EDTA.
Homogenates were centrifuged and supernatants collected for catechol-
amine determinations. Total tumor catecholamine content was calcu-
lated by multiplying tumor tissue concentration of catecholamines (epi-
nephrine  norepinephrine) by tumor volume. The relations between
tumor volume, tumor catecholamine content, and summed plasma con-
TABLE 1. Patient characteristics
Patient
no.
Sex, age at
diagnosis (yr)
SDHB
mutation
Primary
tumor location
Primary tumor
size (cm)
Metastases
location
Time until
metastases (yr)
Symptoms at
initial diagnosis
S1 M, 38 C196Y L retroperitoneal 15  10  7 lu, b 0 Pain
S2 M, 39 R46Q L extra-adrenal abd 15  11.7  7.5 ln, me, b 0 Pain
S3 M, 60 W200C Aortic bifurcation 3  1  2 ln, lu, b 0.2 Pain, DVT, hematuria
S4 M, 29 G96D L pararenal 18  16  8.5 b 1.7 Pain, fatigue
C1 F, 37 V140F Pelvic 15  9  6.2 ln, li 0.8 None, incidentaloma
C2 F, 24 I127S L juxta-adrenal 3.5  2.8  3.8 b 3.5 CA sympt, pain
C3 F, 45 V140F R paraaortic abd 5.5  4  3.5 ln 0 CA sympt, dizziness
C4 M, 10 R46X L para-adrenal 3  3  2 ln, lu, b, me 0 CA sympt, fatigue
C5 F, 34 R115X Bladder 2.7  2  1.5 ln, lu 2.5 CA sympt
C6 M, 35 IVS3-1GC L pararenal 14.5  8  7.5 ln, li, b 0.5 CA sympt
b, Bone; CA sympt, symptoms related to catecholamines excess; DVT, deep venous thrombosis; F, female; L, left; li, liver; ln, abdominal lymph node; lu, lung; M, male;
me, mediastinum; R, right.
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centrations of metanephrine and normetanephrine were evaluated by
log-linear regression.
Electron microscopy
Electron microscopy of PGLwas performed to examine the presence
andmorphology of secretory granules, the intracellular storage units for
catecholamines. Paraffin-embedded tissue samples of primary tumors
from patient nos. S1–4, and C2 and 4were deparaffinated in xylene and
embedded in epoxy resin for electron microscopy. Ultrathin sections
were double stained with uranyl acetate and lead citrate, and examined
and photographed with a Phillips CM10 electron microscope (Phillips
Electronic Instruments, Mahway, NJ).
Tyrosine hydroxylase immunohistochemistry
Theenzyme tyrosinehydroxylase converts L-tyrosine to L-dihydroxy-
phenylalanine,which is the initial and rate-limiting step in catecholamine
synthesis (17). Immunohistochemical staining for tyrosine hydroxylase
was performed as previously described (18) on formalin-fixed paraffin-
embedded sections of primary tumors, which were available in all pa-
tients, i.e. in nos. S1–4 and C1–6. Sections were preincubated for 1 h in
a blocking solution consisting of 0.1 M PBS containing 10 mM Tris PBS
(TPBS), 0.3%Triton X-100, 0.1% (wt/vol) sodium azide, and 10% nor-
mal donkey serum (Jackson ImmunoResearch Laboratories, Inc., West
Grove, PA). Sections were incubated with mouse monoclonal antibody
to tyrosine hydroxylase (1:250; ImmunoStar, Inc., Hudson,WI) for 24 h
at 4 C in a humidified chamber. Sections were washed (3  10 min in
TPBS) and then incubated for 4 h at room temperature with secondary
antibody (donkey antimouse Alexa Fluor 488, 1:500;Molecular Probes,
Inc., Eugene, OR). Sections were washed (3  10 min in TPBS) and
mounted in ProLong Gold Antifade (Molecular Probes). Rat adrenal
sections, used as negative controls, were processed concurrently accord-
ing to the samemethods,withomissionof theprimary antibody. Sections
were examined using aZeiss LSMPASCAL5 (Carl ZeissMicroImaging,
Inc., Thornwood, NY) equipped with Argon/2 458–514 to excite fluo-
rescein isothiocyanate. Emission was collected through the fluorescein
isothiocyanate filter (bandpass 505–530) using a 25 NeoFluor objec-
tive lens, with pinhole, detector gain, and laser power adjusted accord-
ingly to acquire approximately 5-m thick sections with few saturated
pixels. Images were acquired with LSM 5 Image Browser software
(Carl Zeiss MicroImaging). Although overall contrast was adjusted,
no other modifications were made. Staining was described as negli-
gible, moderate, or intense, and the distribution pattern of immuno-
reactive cells was noted.
Results
Case histories of patients with biochemically silent PGL
No. S1 (index case)
At age 38 yr, this male patient underwent a workup of left-
sided abdominal pain, including computed tomography (CT) of
the abdomen. This revealed a 15-cm left retroperitoneal mass
and a small lesion of the right lower lung lobe. The lung lesion
was removed by wedge excision, and identified as a metastatic
lesion of a PGL. He lacked a history of signs and symptoms
classically related to catecholamine excess; more specifically,
there was no hypertension or reports of palpitations, headache,
and diaphoresis. He was then referred to the NIH where a ret-
roperitoneal PGL was resected along with the left kidney and
spleen.Plasmaconcentrationsandurineoutputofcatecholaminesand
metanephrines were normal before and after surgery (Table 2).
However, plasma levels of chromogranin A were elevated and
remained elevated at 60%above the upper reference limit (URL) TA
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after surgery. An additional left pulmonary metastasis was re-
moved. One year later, anatomical imaging and [123]-metaio-
dobenzylguanidine (MIBG) scintigraphy showed additional me-
tastases in the left iliac bone and the second thoracic vertebral
body. The patient underwent lumbar vertebroplasty, [131]-
MIBG treatment, and chemotherapy (cyclophosphamide, vin-
cristine, dacarbazine) resulting in stable disease. An underlying
C196Y SDHB mutation was identified.
Concentrations of catecholamines in the primary retroperi-
toneal tumor were 0.9 nmol/g each for norepinephrine and epi-
nephrine, and 0.03 nmol/g for dopamine. The tissue concentra-
tion of total catecholamines (1.8 nmol/g) of the tumor from this
index patient was less than 0.01% that of the median (20,410
nmol/g) for the 136 patients with catecholamine-producing tu-
mors and less than 0.4% the lowest concentration (521 nmol/g)
for any single tumor. Consequently, the data point for this pa-
tient fell completely outside of the normal relationship between
tumorvolumeandplasmaconcentrationsof totalmetanephrines
(Fig. 1,upper panel).However, after correction for differences in
tissue catecholamine concentrations, the data point for the pa-
tient did fit in with the expected relationship of total tissue cat-
echolamine contents with plasma concentrations of metaneph-
rines (Fig. 1, lower panel). The findings of normal plasma
metanephrines, despite large tumor volume in no. S1, represent-
ing a mismatch in the usual relationship between tumor volume
and plasma metanephrines, could not be explored in the addi-
tional three cases (nos. S2–4) because theywere operatedoutside
the NIH, and no frozen tumor tissue was available for tissue
catecholamine determinations.
Additional cases (nos. S2–4)
No. S2
Fromage22yr, thismale patient experienced lowerbackpain
after exercise.He soughtmedical attention after the pain became
constant at age 26 yr. CT showed lytic lesions of the third and
fourth lumbar vertebral bodies, a 15-cm necrotic mass in the
caudal retroperitoneum, and multiple pathologically enlarged
lymph nodes of the mediastinum. The retroperitoneal mass was
removed, along with several regional lymph nodes. A PGL with
local lymph node involvement and distant metastases was diag-
nosed.Thepatient’s historywasnegative for signs and symptoms
of catecholamine excess. Despite the presence of metastases,
plasma concentrations of catecholamines and their O-methyl-
ated metabolites were repeatedly normal, except for an isolated
slight increase in epinephrine, which was not related to elevated
metanephrine (Table 2). In addition, there was a one-time in-
crease of urine dopamine just above the upper reference level,
whereas plasma dopamine was normal. The plasma concentra-
tion of chromogranin A was elevated 2.9-fold above the upper
limit of normal. The patient underwent six cycles of chemother-
apy (cyclophosphamide, vincristine, dacarbazine) without re-
sponse, and lumbar vertebroplasty. At age 29 yr, he had pro-
gressive disease, as shown by [123]-MIBG scintigraphy, and
started [131]I-MIBG treatment. He is a carrier of an R46Q
SDHB mutation.
No. S3
At age 58 yr, this patient developed pelvic pain, hematuria,
weight loss, and deep venous thrombosis of the left leg. CT
showed a 6-cm retroperitoneal mass adherent to the aortic bi-
furcation, with extension into the bony pelvis and the lumbosa-
cral spine. During exploratory surgery, the mass was partially
resected, and identified as a partially necrotic PGLwith neuronal
and lymphovascular invasion. The patient had no signs or symp-
toms of catecholamine excess. Subsequently, multiple vertebral
and pulmonary metastases were found on CT and [123]-MIBG
scintigraphy.He underwent cyber knife surgery of the remaining
abdominal tumor, and external beam radiation therapy of ver-
tebral lesions, resulting inpartial pain relief.Hewas then referred
to the NIH for further evaluation and treatment of metastatic
PGL. Plasma concentrations and urine output of catecholamines
and metanephrines were repeatedly normal, except for an iso-
lated increase in plasma norepinephrine in the presence of a nor-
mal normetanephrine (Table 2). The plasma concentration of
chromogranin A was elevated by 80% above the upper limit of
normal. One year after the diagnosis, he underwent [131]I-
MIBG treatment, resulting in further symptomatic relief. How-
ever, during the following 2 yr, he had gradually progressive
disease. He is a carrier of a W200C SDHB mutation.
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FIG. 1. Relationship between tumor volume and plasma free metanephrines
(MN) (upper panel), and between tumor catecholamine content and plasma free
metanephrines (lower panel) in catecholamine-secreting PGLs. The arrows mark
the data points for the biochemically silent tumor in patient no. S1. E, Epinephrine;
NE, norepinephrine; NMN, normetanephrine.
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No. S4
This male patient presented at age 29 yr with an 8-month
history of a left-sided varicocele and upper abdominal discom-
fort, which led to the discovery of an 18-cm mass near the left
renal hilumonCT. Fromearly childhood on, he had experienced
recurrent anxiety attacks, accompanied by palpitations, head-
ache, sweating, and occasional chest pain. He had a history of
uncomplicated surgery of a left-sided cystic hydroma of the neck
at age 23 yr. The retroperitoneal mass was resected, along with
the left kidney and regional lymph nodes. The histopathology
revealed an 18-cm PGL with vascular invasion, and tumor-neg-
ative lymph nodes. During follow-up at the NIH, 1.7 yr after
surgery, multiple [123]-MIBG positive metastatic lesions through-
out the skeleton were found. Plasma concentrations and urine
output of catecholamines and O-methylated metabolites were
consistently normal (Table 2). Plasma chromograninA level was
not determined. [131]I-MIBG treatment resulted in a partial re-
sponse. He was found to have a G69D SDHB mutation.
Cases with catecholamine-secreting tumors
Plasma and urine findings in patients with SDHB-related cat-
echolamine-secreting tumors were consistent with hypersecre-
tion of norepinephrine and dopamine in patient nos. C1, 4, and
6, and norepinephrine alone in patient nos. C2, 3, and 5 (Table
2). As shown in Table 2, themetastases in no. C1 predominantly
hypersecreted dopamine. However, before resection of the pri-
mary tumor at the referring institute, there were consistent ele-
vations of plasma norepinephrine and normetanephrine, and
urinary excretion of norepinephrine and normetanephrine (2.1-
to 3.8-fold above the upper limits of normal).
Electron microscopy and tyrosine hydroxylase
immunohistochemistry
On electron microscopy, the catecholamine-secreting PGL
and biochemically silent PGLs showed a similar cellular mor-
phology (Fig. 2). This included the presence of electron-dense
secretory granules in the cells of both tumor types. In the tumor
of one patient (no. S1), the secretory granules appeared to be
larger and less dense compared with the other tumors (Fig. 2).
Tyrosine hydroxylase stainingwas intense in rat adrenalmedulla
and throughout all sections obtained from the PGLs that pro-
duced catecholamines from patient nos. C1–6 (Fig. 3). Staining
was negligible in the tumors of all four patients (nos. S1–4) in
whom there was no evidence of catecholamine hypersecretion.
Discussion
Patientswith catecholamine-producingPGLsbutnormalplasma
concentrationsandurinaryoutputsof catecholamines invariably
do have elevated plasma and urine concentrations of metaneph-
rines (3, 4). However, plasma concentrations of metanephrines
can be normal in patientswith very small tumors or in thosewith
rare PGLs that only produce dopamine (5, 6, 13).We now show
that plasma concentrations and urinary outputs of metaneph-
rines can also be normal in some cases of largemetastatic SDHB-
related PGLs.We found that the lack of catecholamine secretion
and metabolism by these tumors results from a defect in the
synthesis rather than in the storage or release of catecholamines,
as indicated by the absence of tyrosine hydroxylase, the rate-
limiting enzyme in catecholamine synthesis (17), but thepresence
of storage vesicles, and the accumulation of MIBG. This report
provides the first unequivocal evidence for the existence of such
truly biochemically silent abdominal PGLs.
The lack of catecholamine hypersecretion poses a significant
diagnostic challenge, as illustrated by the present and previously
reported cases (8–10, 12, 13). Due to the absence of typical
symptoms of catecholamine excess such as headache, palpita-
tions, diaphoresis, and anxiety, the diagnosis of such tumors is
usually delayed until an advanced stage of the disease. This delay
FIG. 3. Tyrosine hydroxylase immunohistochemistry in two catecholamine-
secreting PGLs (patient nos. C2 and C4, upper panels) in a biochemically silent
PGL (patient no. S1, left-lower panel) and in rat adrenal medulla (right-lower
panel). Tyrosine hydroxylase activity is abundant in the human and rat controls
but absent in the silent tumor.
FIG. 2. Electron microscopy of a catecholamine-secreting PGL (patient no. C4,
left panel) and a biochemically silent PGL (patient no. S1, right panels). Red
arrows indicate examples of secretory granules. Secretory granules are present in
both the secreting and silent tumor.
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may contribute to the development ofmalignant disease. Similar
to PGLs that secrete only dopamine (5, 6), patients with bio-
chemically silentPGLpresentwithadvanceddiseaseandatypical
symptoms caused by tumor mass effects rather than catechol-
amine excess.
Biochemically silent abdominal PGLs appear to share fea-
tures with parasympathetic head and neck PGLs, which invari-
ably do not secrete or produce catecholamines (19). Similar to
head and neck PGLs, one nonsecreting abdominal PGLwas pre-
viously shown to be negative on Gomori’s stain for chromaffin
tissue (12, 20). However, the actual catecholamine content of
tumor tissuewas notmeasured in any of the previously reported,
supposedly biochemically silent tumors (8–13). We now clearly
show in our index patient that tumor tissue concentration of
epinephrine, norepinephrine, and dopamine was negligible
(0.01%) compared with those of other patients with abdom-
inal and adrenal PGLs. For the measurement of tumor cat-
echolamines, frozen tissue specimens are required, which were
not available for the additional three cases. However, these
PGLs very likely also represented truly silent tumors because,
despite their large size, plasma and urinary metanephrines
were not increased, and there was a lack of staining for ty-
rosine hydroxylase.
Biochemically silent tumors may develop from subsets of un-
differentiated cells originating from the primitive neural crest
that lack the ability to produce catecholamines. Alternatively,
tumor cells may specifically lose the machinery to produce cat-
echolamines as part of tumor dedifferentiation; the loss of ty-
rosine hydroxylase may occur before the PGL is large enough to
secrete significant amounts of catecholamines. The latter might
explain why none of the present patients had a transient history
of endocrine symptoms. In line with the possibility of tumor
dedifferentiation, tyrosine hydroxylase immunoreactivity has
been demonstrated elsewhere in three primary head and neck
PGLs, butnot in theirmetastatic lesions (21).Other thanpatients
with small tumors (1 cm) orwith head and neck PGLs, the four
reported here are the only patients in whom plasma concentra-
tions ofO-methylatedmetabolites have been normal in over 350
cases we have studied to date. Remarkably, all four patients had
SDHB mutations. Whether the absence of catecholamine pro-
duction and tyrosine hydroxylase is specifically linked to the
SDHB-mutation remains to be elucidated. In most previously
described cases of biochemically silent PGL, the underlying ge-
notypeswere not reported.We found that 10%of SDHB-related
abdominal PGLs are biochemically silent (11). In the present
study, secreting PGLs of the SDHB genotype served as controls.
Control samples showed abundant tyrosine hydroxylase stain-
ing, a feature that is generally observed in the normal adrenal
medulla and across sporadic and familial PGLs of different ge-
notypes (18, 22–24).
Chromaffin cells containgranules thatmainly serveas storage
units for catecholamines, which will target, dock, and fuse with
the plasma membrane to allow stimulus-dependent secretion
(25). We observed similar expression of granules in PGLs that
both produced or did not produce catecholamines. The presence
of such granules in the biochemically silent PGLs together with
chromogranin A immunoreactivity indicates that despite the ab-
sence of tyrosine hydroxylase and the lack of catecholamine syn-
thesis, the tumorsdid expressmanyother components associated
with the vesicular storage and secretory apparatus. Despite nor-
mal metanephrines, plasma concentrations of chromogranin A
were consistently elevated in all three patients with biochemi-
cally silent PGLs inwhom the analytewasmeasured. These find-
ings indicate that as an alternative biochemical parameter,
plasma chromogranin A may be particularly valuable in the set-
ting of biochemically silent PGLs. The accumulation of the ra-
diotracerMIBG, a catecholamine analog that is taken up by and
stored in secretory granules, provides indirect evidence that the
functional capacity of these granules is intact in biochemically
silent PGLs.
In conclusion, we have established that the lack of catechol-
amine secretion in biochemically silent abdominal PGLs is not
due to defects in the mechanisms of storage or secretion of cat-
echolamines but, instead, reflects a defect in catecholamine syn-
thesis resulting in a near complete absence of releasable stores.
The defect is identified as an absence of tyrosine hydroxylase, the
enzyme that catalyzes the initial and rate-limiting step in cate-
cholaminebiosynthesis. This phenotype appears tobe associated
with mutations of the SDHB gene, indicating that screening for
tumors in identified carriers of that mutation should not be lim-
ited to biochemical tests of catecholamine excess (e.g. plasma or
urinary fractionated metanephrines). Additional measurements
of chromogranin A or even imaging studies seem warranted for
excluding nonfunctional PGLs in such patients.
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